Emergent Product Development UK Limited

Microscience Limited

Vmax Ltd.

Robert Graham Feldman

Gordon Dougan

Joseph David Santangelo

Paul Howard Everest

David William Holden

Jacqueline Elizabeth Shea

Joanne Christine Moore

Richard James Dobson

Rebecca Kerry Wilson

Martin John Glenton Hughes

Jonathan Douglas Lane

Zoe Hindle

Enda Elizabeth Clarke

Caroline Joanne Henwood

Liqing Zhou

Helen Rachel Crooke

The present invention pertains to amicroorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing ainfection in a patient.

Attenuated microorganisms for the treatment of infection

A protein from Group Bis shown to be an outer surface protein and is a useful target for antimicrobial therapy.

Genes and proteins, and their use

According to the present invention, a series of genes are identified in Group B Streptococcus, the products of which may be associated with the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines to immunize a patient against microbial infection.

According to the present invention, a series of genes are identified in Group B, the products of which may be located on the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines for the immunization of a patient against microbial infection.

NADP-dependent glyceraldehyde-3-phosphate dehydrogenase for therapeutic use

A series of genes fromare shown to encode products which are implicated in virulence. The identification of these genes therefore allows attenuated microorganisms to be produced. Furthermore, the genes or their encoded products can be used in the manufacture of vaccines for therapeutic application.

Virulence genes, proteins, and their use

The present invention is based on the identification of a series of virulence genes inK1, the products of which may be implicated in the pathogenicity of the organisms. The identification of the genes allows them, or their expressed products, to be used in a number of ways to treat infection.

Virulence genes and proteins, and their use

According to the present invention, a series of genes are identified in Group B Streptococcus, the products of which may be associated with the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vacaccines to immunize a patient against microbial infection.

Genes and proteins and their use

The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.

Growing community of inventors

Berkshire, United Kingdom

Robert Graham Feldman